263 related articles for article (PubMed ID: 29181019)
1. Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate.
Olokpa E; Moss PE; Stewart LV
PPAR Res; 2017; 2017():9456020. PubMed ID: 29181019
[TBL] [Abstract][Full Text] [Related]
2. The Androgen Receptor Regulates PPARĪ³ Expression and Activity in Human Prostate Cancer Cells.
Olokpa E; Bolden A; Stewart LV
J Cell Physiol; 2016 Dec; 231(12):2664-72. PubMed ID: 26945682
[TBL] [Abstract][Full Text] [Related]
3. The role of peroxisome proliferator-activated receptor gamma in prostate cancer.
Elix C; Pal SK; Jones JO
Asian J Androl; 2018; 20(3):238-243. PubMed ID: 28597850
[TBL] [Abstract][Full Text] [Related]
4. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K epoxide reductase regulation of androgen receptor activity.
Tew BY; Hong TB; Otto-Duessel M; Elix C; Castro E; He M; Wu X; Pal SK; Kalkum M; Jones JO
Oncotarget; 2017 Feb; 8(8):13818-13831. PubMed ID: 28099154
[TBL] [Abstract][Full Text] [Related]
8. A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling.
Esmaeili M; Pungsrinont T; Schaefer A; Baniahmad A
J Mol Med (Berl); 2016 Oct; 94(10):1167-1179. PubMed ID: 27305909
[TBL] [Abstract][Full Text] [Related]
9. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways.
Chintharlapalli S; Papineni S; Safe S
Mol Pharmacol; 2007 Feb; 71(2):558-69. PubMed ID: 17093136
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.
Yang CC; Ku CY; Wei S; Shiau CW; Chen CS; Pinzone JJ; Ringel MD; Chen CS
Mol Pharmacol; 2006 May; 69(5):1564-70. PubMed ID: 16452400
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma in human prostate carcinoma.
Nakamura Y; Suzuki T; Sugawara A; Arai Y; Sasano H
Pathol Int; 2009 May; 59(5):288-93. PubMed ID: 19432669
[TBL] [Abstract][Full Text] [Related]
12. Different roles of peroxisome proliferator-activated receptor gamma isoforms in prostate cancer.
Salgia MM; Elix CC; Pal SK; Jones JO
Am J Clin Exp Urol; 2019; 7(3):98-109. PubMed ID: 31317050
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.
Powell SM; Christiaens V; Voulgaraki D; Waxman J; Claessens F; Bevan CL
Endocr Relat Cancer; 2004 Mar; 11(1):117-30. PubMed ID: 15027889
[TBL] [Abstract][Full Text] [Related]
14. Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?
Isaacs JT
Am J Clin Exp Urol; 2018; 6(2):55-61. PubMed ID: 29666833
[TBL] [Abstract][Full Text] [Related]
15. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
[TBL] [Abstract][Full Text] [Related]
16. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
[TBL] [Abstract][Full Text] [Related]
17. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
19. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
